Government-Owned Inventions; Availability for Licensing, 7781-7782 [E6-2015]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 30 / Tuesday, February 14, 2006 / Notices
Estimated Total Annual Burden
Hours Requested: 1125.
The annualized cost to respondents is
estimated at $87,939. There are no
Capital Costs to report. There are no
Operating or Maintenance Costs to
report.
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact Dr. Flora Katz,
Fogarty International Center, National
Institutes of Health, 31 Center Drive,
Building 31, Bethesda, MD 20892–2220
or call non-toll-free number 301–402–
9591 or E-mail your request, including
your address to: KatzF@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60-days of the date of
this publication.
Dated: February 1, 2006.
Richard Miller,
Executive Officer, FIC, National Institutes of
Health.
[FR Doc. E6–2014 Filed 2–13–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
rmajette on PROD1PC67 with NOTICES
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
VerDate Aug<31>2005
14:46 Feb 13, 2006
Jkt 208001
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of federally
funded research and development.
Foreign patent applications are filed on
selected inventions to extend market
coverage for companies and may also be
available for licensing.
Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
ADDRESSES:
Autoantibody Screening for Cancer
Diagnosis
Yoon S. Cho-Chung (NCI).
U.S. Provisional Application filed (HHS
Reference No. E–057–2006/0-US–01).
Licensing Contact: David A.
Lambertson; 301/435–4632;
lambertsond@mail.nih.gov.
There are a number of specific
antigens, such as alpha-fetal protein
(AFP), nonmucinous ovarian cancer
antigen (CA125), vascular endothelial
growth factor (VEGF), prostate-specific
antigen (PSA), which are secreted into
the serum of patients who have
particular cancers. Kits for detecting
these antigens are generally used as a
means of diagnosing patients as having
a specific cancer. However, the current
methods suffer from a lack of
sensitivity.
The instant technology provides a
method for the early diagnosis of
different cancers that does not suffer the
drawbacks of the current assays. The
inventors observed that auto-antibodies
against the cancer marker antigens can
be detected in the serum of patients
with particular cancers. This new
technology is designed to screen for the
autoantibodies for a spectrum of
secreted tumor antigens in a single assay
(BBA, in press). This provides a highly
sensitive assay for diagnosing cancer at
an early stage, or when the tumor is of
a very small size. Claims of the instant
invention are drawn to methods and kits
for performing this analysis as a means
of diagnosing cancer.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
7781
Therapeutic HIV Vaccine Vectors for
Individuals Receiving Antiretroviral
Therapy
Barbara K. Felber et al. (NCI).
U.S. Provisional Application filed 09 Jul
2004 (HHS Reference No. E–249–
2004/0-US–01); PCT Application No.
PCT/US2005/024498 filed 11 Jul 2005
(HHS Reference No. E–249–2004/1PCT–01);
PCT Application No. PCT/US01/45624
filed 01 Nov 2001, which published
as WO 02/36806 on 10 May 2002
(HHS Reference No. E–308–2000/0PCT–02);
National Stage filed in EP, CA, AU, JP,
and U.S. (HHS Reference No. E–308–
2000/0-US–07).
Licensing Contact: Susan Ano; 301/
435–5515; anos@mail.nih.gov.
Antiretroviral therapy (ART) against
HIV leads to control of viremia, but it
does not eradicate the virus. Thus,
interruption of ART leads to virus
rebound. In addition, prolonged ART is
associated with toxicity and
development of virus resistance. The
technology describes the use of DNA
vaccine vectors that produce either
secreted or intracellularly degraded
antigens for administration to
individuals receiving ART. These DNA
vectors have recently been shown to
work unusually well in controlling
viremia when administered as DNA
vaccines to SIV-infected monkeys that
are undergoing treatment with
antiretroviral agents. The current
technologies would decrease the drug
dependence and assist in clearing or
reducing virus burden.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
Haplotypes of Human Bitter Taste
Receptor Genes
Dennis Drayna and Un-Kyung Kim
(NIDCD).
PCT International Application No. PCT/
US2004/019489, filed 18 June 2004
(priority date 19 June 2003),
International Publication No. WO
2005/007891, Publication Date 27
January 2005 and global IP (HHS
Reference Nos. E–222–2003/0 and E–
222–2003/1).
Licensing Contact: Susan Carson,
D.Phil., 301 435–5020;
carsonsu@mail.nih.gov.
Bitter taste has evolved in mammals
as a crucial, important warning signal
against ingestion of poisonous or toxic
compounds. However, many beneficial
compounds are also bitter, and taste
masking of bitter tasting pharmaceutical
E:\FR\FM\14FEN1.SGM
14FEN1
rmajette on PROD1PC67 with NOTICES
7782
Federal Register / Vol. 71, No. 30 / Tuesday, February 14, 2006 / Notices
compounds is a billion dollar industry.
The diversity of compounds that elicit
bitter-taste sensations is very large and
more than two dozen members of the
T2R bitter taste receptor family have
been identified. Individuals are now
known to be genetically predisposed to
respond or not to respond to the bitter
taste of a number of substances. For
example, large individual differences in
the perception of bitterness have been
well documented in compounds as
different as nicotine, thiocyanates such
as those found in cruciferous vegetables,
and many bitter beta-glucopyranosides.
This may have broad implications for
nutritional status and tobacco use and
common allelic variants of a member of
the T2R bitter taste receptor gene family
have been shown to underlie variation
in the ability to taste
phenylthiocarbamide (PTC) [Science
(2003) 299, 1221–1225; HHS Ref No: E–
169–2001/0].
Scientists at the NIDCD have
extended these results to other bitter
taste receptors and have sequenced 22
of the 24 known T2R genes in a series
of populations worldwide, including
Northern Europeans, Hungarians,
Japanese, Cameroonians, Pygmies and
South American Indians and the present
invention includes these isolated
sequences and their variants. This
includes a total of 127 SNPs and 103
different protein coding haplotypes,
including those defined for the PTC
Receptor (T2R38) [E–169–2001/0]. The
inventors showed that 77% of the SNPs
identified caused an amino acid
substitution in the encoded receptor
protein, giving rise to a very high degree
of receptor protein variation in the
population (Kim et al. (2005) Human
Mutation 26, 199–204). The frequencies
of these different haplotypes have been
shown to differ in different populations
which will aid in population-specific
studies, such as those targeting
differences in taste perception between
Europeans and Asians, for example.
The invention available for licensing
includes these novel SNPs and
haplotypes and methods of use, which
can be used to better identify and
characterize different groups of
individuals within and between
populations that vary in their bitter taste
abilities. This is important to the food
and flavoring industry, for example,
where these variants can be used to aid
in the development of a variety of taste
improvements in foods and orally
administered medications. [Also
available for licensing in the Human
Taste Receptor Haplotype patent
portfolio is HHS Ref No. E–169–2001/0PCT–02: Phenylthiocarbamide Taste
Receptor, International Publication No.
VerDate Aug<31>2005
14:46 Feb 13, 2006
Jkt 208001
WO 2003/008627, PCT filed July 19,
2002 and global IP, and HHS Ref. No
099–2005/0: Human Sweet and Umami
Taste Receptor Genes, U.S. Provisional
Patent Application No. 60/671,173 filed
April 2005].
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
Dated: February 2, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–2015 Filed 2–13–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby give of a meeting of the Board
of Scientific Counselors for Basic
Sciences National Cancer Institute.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The meeting
will be closed to the public as indicated
below in accordance with the provisions
set forth in section 552b(c)(6), Title 5
U.S.C., as amended for the review,
discussion, and evaluation of individual
intramural programs and projects
conducted by the National Cancer
Institute, including consideration of
personnel qualifications and
performance, and the competence of
individual investigators, the disclosure
of which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Board of Scientific
Counselors for Basic Sciences National
Cancer Institute.
Date: March 13, 2006.
Open: 8 a.m. to 10:30 a.m.
Agenda: Joint Session of NCI, Board of
Scientific Advisors and Boards of Scientific
Counselors.
Place: National Institutes of Health,
National Cancer Institute, 9000 Rockville
Pike, Building 31, Conference Room 10,
Bethesda, MD 20892.
Closed: 11 a.m. to 7:30 p.m.
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
National Cancer Institute, 9000 Rockville
Pike, Building 31, Conference Room 6,
Bethesda, MD 20892.
Contact Person: Florence E. Farber, PhD,
Executive Secretary, Office of the Director,
National Cancer Institute, National Institutes
of Health, 6116 Executive Boulevard, Room
2115, Bethesda, MD 20892. 301–496–7628.
ff6p@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
into the building by non-government
employees. Persons without a government
I.D. will need to show a photo I.D. and signin at the security desk upon entering the
building.
(Catalogue of Federal Domestic
Assistance Program Nos. 93.392, Cancer
Construction; 93.393, Cancer Cause and
Prevention Research; 93.394, Cancer
Detection and Diagnosis Research;
93.395, Cancer Treatment Research;
93.396, Cancer Biology Research;
93.397, Cancer Centers Support; 93.398,
Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of
Health, HHS)
Dated: February 1, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–1323 Filed 2–13–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
Board of Scientific Counselors for
Clinical Sciences and Epidemiology
National Cancer Institute.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public as indicated below in accordance
E:\FR\FM\14FEN1.SGM
14FEN1
]]>Agencies
[Federal Register Volume 71, Number 30 (Tuesday, February 14, 2006)]
[Notices]
[Pages 7781-7782]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-2015]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Autoantibody Screening for Cancer Diagnosis
Yoon S. Cho-Chung (NCI).
U.S. Provisional Application filed (HHS Reference No. E-057-2006/0-US-
01).
Licensing Contact: David A. Lambertson; 301/435-4632;
lambertsond@mail.nih.gov.
There are a number of specific antigens, such as alpha-fetal
protein (AFP), nonmucinous ovarian cancer antigen (CA125), vascular
endothelial growth factor (VEGF), prostate-specific antigen (PSA),
which are secreted into the serum of patients who have particular
cancers. Kits for detecting these antigens are generally used as a
means of diagnosing patients as having a specific cancer. However, the
current methods suffer from a lack of sensitivity.
The instant technology provides a method for the early diagnosis of
different cancers that does not suffer the drawbacks of the current
assays. The inventors observed that auto-antibodies against the cancer
marker antigens can be detected in the serum of patients with
particular cancers. This new technology is designed to screen for the
autoantibodies for a spectrum of secreted tumor antigens in a single
assay (BBA, in press). This provides a highly sensitive assay for
diagnosing cancer at an early stage, or when the tumor is of a very
small size. Claims of the instant invention are drawn to methods and
kits for performing this analysis as a means of diagnosing cancer.
In addition to licensing, the technology is available for further
development through collaborative research opportunities with the
inventors.
Therapeutic HIV Vaccine Vectors for Individuals Receiving
Antiretroviral Therapy
Barbara K. Felber et al. (NCI).
U.S. Provisional Application filed 09 Jul 2004 (HHS Reference No. E-
249-2004/0-US-01); PCT Application No. PCT/US2005/024498 filed 11 Jul
2005 (HHS Reference No. E-249-2004/1-PCT-01);
PCT Application No. PCT/US01/45624 filed 01 Nov 2001, which published
as WO 02/36806 on 10 May 2002 (HHS Reference No. E-308-2000/0-PCT-02);
National Stage filed in EP, CA, AU, JP, and U.S. (HHS Reference No. E-
308-2000/0-US-07).
Licensing Contact: Susan Ano; 301/435-5515; anos@mail.nih.gov.
Antiretroviral therapy (ART) against HIV leads to control of
viremia, but it does not eradicate the virus. Thus, interruption of ART
leads to virus rebound. In addition, prolonged ART is associated with
toxicity and development of virus resistance. The technology describes
the use of DNA vaccine vectors that produce either secreted or
intracellularly degraded antigens for administration to individuals
receiving ART. These DNA vectors have recently been shown to work
unusually well in controlling viremia when administered as DNA vaccines
to SIV-infected monkeys that are undergoing treatment with
antiretroviral agents. The current technologies would decrease the drug
dependence and assist in clearing or reducing virus burden.
In addition to licensing, the technology is available for further
development through collaborative research opportunities with the
inventors.
Haplotypes of Human Bitter Taste Receptor Genes
Dennis Drayna and Un-Kyung Kim (NIDCD).
PCT International Application No. PCT/US2004/019489, filed 18 June 2004
(priority date 19 June 2003), International Publication No. WO 2005/
007891, Publication Date 27 January 2005 and global IP (HHS Reference
Nos. E-222-2003/0 and E-222-2003/1).
Licensing Contact: Susan Carson, D.Phil., 301 435-5020;
carsonsu@mail.nih.gov.
Bitter taste has evolved in mammals as a crucial, important warning
signal against ingestion of poisonous or toxic compounds. However, many
beneficial compounds are also bitter, and taste masking of bitter
tasting pharmaceutical
[[Page 7782]]
compounds is a billion dollar industry. The diversity of compounds that
elicit bitter-taste sensations is very large and more than two dozen
members of the T2R bitter taste receptor family have been identified.
Individuals are now known to be genetically predisposed to respond or
not to respond to the bitter taste of a number of substances. For
example, large individual differences in the perception of bitterness
have been well documented in compounds as different as nicotine,
thiocyanates such as those found in cruciferous vegetables, and many
bitter beta-glucopyranosides. This may have broad implications for
nutritional status and tobacco use and common allelic variants of a
member of the T2R bitter taste receptor gene family have been shown to
underlie variation in the ability to taste phenylthiocarbamide (PTC)
[Science (2003) 299, 1221-1225; HHS Ref No: E-169-2001/0].
Scientists at the NIDCD have extended these results to other bitter
taste receptors and have sequenced 22 of the 24 known T2R genes in a
series of populations worldwide, including Northern Europeans,
Hungarians, Japanese, Cameroonians, Pygmies and South American Indians
and the present invention includes these isolated sequences and their
variants. This includes a total of 127 SNPs and 103 different protein
coding haplotypes, including those defined for the PTC Receptor (T2R38)
[E-169-2001/0]. The inventors showed that 77% of the SNPs identified
caused an amino acid substitution in the encoded receptor protein,
giving rise to a very high degree of receptor protein variation in the
population (Kim et al. (2005) Human Mutation 26, 199-204). The
frequencies of these different haplotypes have been shown to differ in
different populations which will aid in population-specific studies,
such as those targeting differences in taste perception between
Europeans and Asians, for example.
The invention available for licensing includes these novel SNPs and
haplotypes and methods of use, which can be used to better identify and
characterize different groups of individuals within and between
populations that vary in their bitter taste abilities. This is
important to the food and flavoring industry, for example, where these
variants can be used to aid in the development of a variety of taste
improvements in foods and orally administered medications. [Also
available for licensing in the Human Taste Receptor Haplotype patent
portfolio is HHS Ref No. E-169-2001/0-PCT-02: Phenylthiocarbamide Taste
Receptor, International Publication No. WO 2003/008627, PCT filed July
19, 2002 and global IP, and HHS Ref. No 099-2005/0: Human Sweet and
Umami Taste Receptor Genes, U.S. Provisional Patent Application No. 60/
671,173 filed April 2005].
In addition to licensing, the technology is available for further
development through collaborative research opportunities with the
inventors.
Dated: February 2, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E6-2015 Filed 2-13-06; 8:45 am]
BILLING CODE 4140-01-P
